NCT07142291View on ClinicalTrials.gov

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

March 31, 2028

Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
DRUG

Cromolyn Sodium (34.2 mg BID)

17.1 mg, BID, oral inhalation

DRUG

Cromolyn Sodium (17.1 mg BID)

34.2 mg, BID, oral inhalation via dry powder inhaler

DRUG

Placebo

Placebo comparator matched to active treatment.

DRUG

Riluzole (100 mg)

50 mg, oral tablet, BID, standard of care treatment

All Listed Sponsors
lead

PhenoNet, Inc.

INDUSTRY